![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 02, 2018 2:13:18 AM
Read https://www.caratherapeutics.com/therapeutic-focus/chronic-pain/
Great Stats re Market Opportunity for Pain Management Solutions. Cara outlines it approach for pain management. Whereas Biel has actipatch approach but Cara talk about "Novel Analgesic" approach.
However CARA has not yet got FDA approval for the product, is not selling products or has not got UK government support via NHS to provide it for patients. But the market cap is 423 Million.
Biel has FDA approval , selling products, is support by NHS and has sales ramping up all over the world and yet is valued at less than 20% of CARA. The only difference is a Nasdaq listing.
Clear Deduction: Biel is an underexposed solution to Chronic pain and will trade will north of 1 cent very soon.
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM